Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLVARI: Folic Acid 10 mg vs 30 mg in Rheumatoid Arthritis
NCT01583959Phase 4Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Apr 2012
- Primary completion
- Nov 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of folic acid in rheumatoid arthritis (RA) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Adverse effects due to methotrexate at 24 weeks and Disease Activity Score 28 joints at 24 weeks. Started Apr 2012; status: completed.
02
Drugs
folic acid
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01583959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01583959.